Crunch Time At EMA For Luspatercept And Glasdegib
Executive Summary
Eight new marketing applications including ones from BMS/Acceleron Pharma and Pfizer are up for an opinion at the April meeting of the European Medicines Agency’s drug evaluation committee, the CHMP.